Latest news with #DLPL
Time of India
25-06-2025
- Business
- Time of India
Dr. Lal PathLabs adds Illumina's NovaSeq X Series to expand genomics capabilities
Mumbai: Diagnostic provider Dr. Lal PathLabs Limited (DLPL) has expanded its genomics division, Genevolve , with the addition of Illumina 's NovaSeq X Series . The integration is expected to enhance the lab's capacity to deliver faster and more accurate genomic insights . The NovaSeq X system incorporates Illumina's XLEAP-SBS chemistry, offering high throughput, improved accuracy, and increased efficiency. It is stated that The NovaSeq X Plus model can process over 20,000 whole genomes per year—more than twice the capacity of Illumina's earlier models. The system is designed to support large-scale genomic research through increased speed and sensitivity. According to DLPL, the investment supports its broader efforts to improve genomic testing capabilities and contribute to the country's growing genomics landscape. Launched in 2019, DLPL's Genevolve unit focuses on DNA-based diagnostics and next-generation sequencing (NGS). The addition of Illumina's technology is expected to further strengthen its offerings in this space. Dr. Lal PathLabs and Illumina also plan to collaborate with India's scientific and medical communities to promote awareness and capacity-building for genomics-based healthcare.
Business Standard
25-06-2025
- Business
- Business Standard
Dr Lal Pathlabs strengthens its genomics capabilities with Illumina's NovaSeq X Series
Dr Lal Pathlabs (DLPL) has expanded its genomics capabilities by adding Illumina's NovaSeq X Series to its dedicated genomics division, Genevolve. With the integration of Illumina's latest technology, DLPL can now deliver faster and more accurate genomic research insights. The NovaSeq X system features Illumina's cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability. The NovaSeq X Plus can generate more than 20,000 whole genomes per year, more than double the throughput of Illumina's previous sequencers. Its unprecedented speed, scale, and accuracy push the limits of what's possible in genetic sequencing. And its powerful technology allows users to unlock previously unimaginable discoveries and advancements. With the addition of Illumina's NovaSeq X Series, we are taking another step forward in driving innovation and scientific excellence, said Mr. Shankha Banerjee, CEO, Dr. Lal PathLabs Limited. This investment allows us to broaden our capabilities and contribute meaningfully to India's evolving genomics landscape. Launched in 2019, Genevolve has swiftly emerged as a DNA-based center of excellence. The addition of Illumina products further strengthens Genevolve's position as a pioneer in next-generation sequencing (NGS), enabling DLPL to deliver actionable, AI-powered insights with greater speed and sensitivity.
Business Upturn
25-06-2025
- Business
- Business Upturn
Dr. Lal PathLabs boots genomics capabilities with Illumina's NovaSeq™ X Series
By Aman Shukla Published on June 25, 2025, 11:39 IST Dr. Lal PathLabs Limited (DLPL), one of India's most trusted names in diagnostics, has taken a major step forward in genomics by adding the advanced NovaSeq™ X Series from Illumina to its dedicated genomics unit, Genevolve. This cutting-edge technology allows DLPL to deliver faster and more accurate results in genetic research. The NovaSeq™ X system, powered by Illumina's XLEAP-SBS™ chemistry, offers top-notch performance with high speed, accuracy, and sustainability. In fact, the NovaSeq X Plus can handle over 20,000 whole genomes per year—twice as much as earlier models. Genevolve, launched in 2019, has quickly made a name for itself as a leader in DNA-based diagnostics and next-generation sequencing (NGS). With the new Illumina platform onboard, DLPL is now even better equipped to offer quick, AI-driven insights that can support smarter healthcare decisions. 'With the addition of Illumina's NovaSeq X Series, we are taking another step forward in driving innovation and scientific excellence,' said Shankha Banerjee, CEO, Dr. Lal PathLabs Limited. 'This investment allows us to broaden our capabilities and contribute meaningfully to India's evolving genomics landscape.' Looking ahead, Dr. Lal PathLabs and Illumina plan to work closely with India's medical and research communities to promote the use of genomics in healthcare, helping unlock new possibilities in personalized medicine. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
&w=3840&q=100)
Business Standard
25-04-2025
- Business
- Business Standard
Dr Lal PathLabs Q4 profit rises 84% on volume growth, geographic expansion
India's largest diagnostics service provider, Dr Lal PathLabs (DLPL), on Friday reported an 81.4 per cent year-on-year (Y-o-Y) increase in consolidated net profit for the March quarter of financial year 2024-25 (Q4FY25) at Rs 156 crore, up from Rs 86 crore reported for the same period last year. The company's revenue from operations also rose to Rs 603 crore in Q4FY25, a 10.5 per cent Y-o-Y growth from Rs 545 crore reported in Q4FY24. On a sequential basis, the company exhibited a flat 59 per cent rise in net profit, while revenue remained flat, from Rs 98 crore and Rs 597 crore reported in Q3FY25, respectively. The company's earnings before interest, tax, depreciation, and amortisation (Ebitda) rose by 16.9 per cent Y-o-Y to Rs 169 crore, with the Ebitda margin coming in at 28.1 per cent in the March quarter compared to 26.5 per cent in the same period last year. The company attributed the strong performance to increased testing volumes and its expanding footprint, particularly in Tier-III and Tier-IV towns. Speaking on the results, DLPL group chief financial officer Ved Prakash Goel said that the strong results were driven by volume growth, and supported by a favourable test and geographic mix, without taking any price hikes. DLPL said that volume-led growth was achieved through deeper penetration in core markets and calibrated expansion in newer regions of the West and South. 'Growing sample and patient volumes are driving increased operating leverage, enabling the company to maintain competitive pricing while realising efficiency gains through optimised IT infrastructure,' it added. Commenting on future plans, Shankha Banerjee, chief executive officer (CEO) at DLPL, said that the company will look to strategically evolve its test portfolio to meet the dynamic needs of healthcare. 'This includes a focused expansion into specialised verticals like genomics and advanced diagnostics, exemplified by our recent launch of the advanced Amyloid Typing test – a first in South Asia,' he added. As of March 31, 2025, DLPL operates 298 clinical laboratories, including a National Reference Lab in Delhi and Regional Reference Labs in Kolkata, Bangalore, and Mumbai. Its network also includes 6,607 patient service centres (PSCs) and 12,365 pick-up points (PUPs), serving individual patients, hospitals, healthcare providers, and corporate clients. On Friday, Dr Lal PathLabs' stocks were up by 4.26 per cent, ending the day's trade at Rs 2,906.55 apiece on the Bombay Stock Exchange (BSE).
